Register now to R3i !
Your login
Your password
Confirm your password
Your email
I agree to receive the R3i newsletter
The Initiative

Prof. Philip Barter

Prof. Philip Barter
University of New South Wales
Short Narrative Biography

Philip Barter graduated in medicine from the University of Adelaide and gained his PhD from the Australian National University. He has held positions in research institutes and universities in Australia and the US and is currently based at the University of New South Wales in Australia where he holds a position as Conjoint Professor of Medicine. He is a fellow of the Royal Australasian College of Physicians. He is the current President of the International Atherosclerosis Society. He is also a member of the executive of the International Chair on Cardiometabolic Risk. He was the 2011 recipient of the Anitschkow Award of the European Atherosclerosis Society.

His basic research interests are plasma lipids and lipoproteins, specifically high density lipoproteins, the factors that regulate them and the mechanism by which they protect against cardiovascular disease. His clinical research involves participation in clinical trials of lipid-lowering agents. He was a member of the steering committees of the FIELD study, the TNT Study, was co-chair of steering committee of the DEFINE study and was chairman of the steering committee of the ILLUMINATE trial. He is currently a member of the steering committees of the REVEAL HPS-3 TIMI-55 trial and the ACCELERATE trial; these are two large-scale clinical outcome trials assessing the ability of new CETP inhibitors to reduce CV risk. He has published more than 300 peer-reviewed research papers on plasma lipids and lipoproteins, their metabolism, regulation, function and relationship to atherosclerosis. He has also written handbooks on HDL and CETP inhibitors
He has had a long-term and ongoing involvement in both the Australian Atherosclerosis Society and the International Atherosclerosis Society. Recognizing that atherosclerosis has become a major global epidemic, he is committed to the development of atherosclerosis research and education programs in countries beyond North America and Western Europe, including South and Southeast Asia, South and Central America, the Middle East and Africa.